Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy

Salvatore Petta, Sanatan Shreay, Luca Degli Esposti, Giulio Marchesini, Jie Ting, Jie Ting, Stefania Saragoni, Maria Letizia Petroni

Risultato della ricerca: Articlepeer review

15 Citazioni (Scopus)


Background and aims: Nonalcoholic steatohepatitis (NASH) may progress to advanced liver disease (AdvLD). This study characterized comorbidities, healthcare resource utilization (HCRU) and associated costs among hospitalized patients with AdvLD due to NASH in Italy. Methods and results: Adult nonalcoholic fatty liver disease (NAFLD)/NASH patients from 2011 to 2017 were identified from administrative databases of Italian local health units using ICD-9-CM codes. Development of compensated cirrhosis (CC), decompensated cirrhosis (DCC), hepatocellular carcinoma (HCC), or liver transplant (LT) was identified using first diagnosis date for each severity cohort (index-date). Patients progressing to multiple disease stages were included in >1 cohort. Patients were followed from index-date until the earliest of disease progression, end of coverage, death, or end of study. Within each cohort, per member per month values were annualized to calculate all-cause HCRU or costs(€) in 2017. Of the 9,729 hospitalized NAFLD/NASH patients identified, 97% were without AdvLD, 1.3% had CC, 3.1% DCC, 0.8% HCC, 0.1% LT. Comorbidity burden was high across all cohorts. Mean annual number of inpatient services was greater in patients with AdvLD than without AdvLD. Similar trends were observed in outpatient visits and pharmacy fills. Mean total annual costs increased with disease severity, driven primarily by inpatient services costs. Conclusion: NAFLD/NASH patients in Italy have high comorbidity burden. AdvLD patients had significantly higher costs. The higher prevalence of DCC compared to CC in this population may suggest challenges of effectively screening and identifying NAFLD/NASH patients. Early identification and effective management are needed to reduce risk of disease progression and subsequent HCRU and costs.
Lingua originaleEnglish
pagine (da-a)1014-1022
Numero di pagine9
Stato di pubblicazionePublished - 2020

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.2700.2701???
  • ???subjectarea.asjc.2700.2712???
  • ???subjectarea.asjc.2900.2916???
  • ???subjectarea.asjc.2700.2705???


Entra nei temi di ricerca di 'Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy'. Insieme formano una fingerprint unica.

Cita questo